Head-to-head · WeighScore
Boston Medical Group vs Virta Health
The verdict
Boston Medical Group takes it — 61.9/100 to 59.7/100.
Boston Medical Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Boston Medical Group is an established medical group running a 12-week compounded GLP-1 weight-loss programme.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Boston Medical Group | Virta Health |
|---|---|---|
| WeighScore | 61.9/100 | 59.7/100 |
| Grade | C | C |
| Scorecard rank | #279 | #336 |
| Semaglutide | $199/mo (starting strength, rising with dose, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | 7 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #336 · C
Strengths
- Offers a Responsible Prescribing track with optimized GLP-1 use
- Clinically monitored medication off-ramp toward nutrition therapy
- Nutrition-first model shown to rival GLP-1 weight loss (about 13% at 1 year)
- Provided at no cost to members through employers and health plans
- Strong evidence base for diabetes reversal and metabolic health
Where it loses points
- Primarily a nutrition program; GLP-1s are a secondary track
- Distributed via employers and health plans, no direct cash-pay
- Deliberately discourages GLP-1 use for most members
- GLP-1 access depends on the specific program the plan selects
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.